D&A at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s D&A?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported D&A of $386K in Q1 2026.
- How has Madrigal Pharmaceuticals, Inc.'s D&A changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s D&A increased by 1.8% year-over-year, from $379K to $386K.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s D&A?
- Over 4 years (2021 to 2025), Madrigal Pharmaceuticals, Inc.'s D&A has grown at a 38.9% compound annual growth rate (CAGR), from $405K to $1.51M.
- What does D&A mean?
- The non-cash expense of spreading the cost of assets over time.
- How do you interpret D&A?
- High levels suggest significant capital investment in infrastructure or intellectual property.
- How does D&A compare across companies?
- Standard across capital-intensive industries; varies based on asset base size and accounting policy.